Early safety check for new c. diff drug in japanese volunteers
NCT ID NCT06639997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of AZD5148, a potential treatment for C. difficile infection, in 16 healthy Japanese adults. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo by injection and were monitored for side effects over about a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIOIDES DIFFICILE INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Sumida-ku, 130-0004, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your dinner plate might fight c. diff: diet study aims to stop repeat infections
- FMT vs antibiotics: which works better Long-Term for c. diff?
- Hospital maps may slash infection spread
- New antibiotic CRS3123 takes on c. diff in early trial
- Gut bacteria capsules take on superbugs in antibiotic patients
- New drug combo shows promise against deadly gut infection